20:04 , Apr 18, 2019 |  BC Innovations  |  Translation in Brief

Agenus scales the AI ALPS

Agenus is using its artificial intelligence, machine learning platform to match cancer patients with the best monotherapy or combination therapy it has, and to uncover mechanisms of resistance to develop new therapies using non-responder data....
19:52 , Feb 1, 2019 |  BC Week In Review  |  Financial News

Agenus to sell blockchain tokens to fund PD-1 development

Agenus Inc. (NASDAQ:AGEN) said Jan. 29 that is seeking to raise up to $100 million via the sale of blockchain-powered tokens tied to clinical anti-PD-1 mAb AGEN2034. The company said the asset-backed digital security is...
19:21 , Jan 29, 2019 |  BC Extra  |  Financial News

Agenus to sell blockchain tokens to fund PD-1 development

Agenus Inc. (NASDAQ:AGEN) is seeking to raise up to $100 million via the sale of blockchain-powered tokens tied to clinical anti-PD-1 mAb AGEN2034. The company said the asset-backed digital security is the first of its...
20:07 , May 18, 2018 |  BC Week In Review  |  Clinical News

Agenus shifts focus to cervical cancer from first-line NSCLC

Agenus Inc. (NASDAQ:AGEN) said in its 1Q18 earnings report that it shifted its developmental strategy to first seek approval of its checkpoint inhibitors as a second-line treatment for cervical cancer instead of as a first-line...
18:23 , Jan 12, 2018 |  BC Week In Review  |  Company News

HealthCare Royalty in vaccine royalty deal with Agenus

Agenus Inc. (NASDAQ:AGEN) will sell to HealthCare Royalty Partners (Stamford, Conn.) royalty rights on sales of vaccines from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) containing Agenus' QS-21 Stimulon adjuvant. The biotech will receive $190 million in cash,...
19:00 , Jun 30, 2017 |  BC Week In Review  |  Clinical News

Agenus reports Phase I data for AEGN1884 in solid tumors

Agenus Inc. (NASDAQ:AGEN) reported interim data from 16 evaluable patients with advanced or refractory solid tumors in a Phase I trial showing that 0.1, 0.3, 1 and 3 mg/kg doses of AGEN1884 led to no...
23:22 , Feb 23, 2017 |  BC Extra  |  Company News

Agenus pointing to its checkpoint inhibitors

Agenus Inc. (NASDAQ:AGEN) is looking past the demise of its Prophage G-200 vaccine in brain cancer and pointing investors to upcoming milestones for its checkpoint inhibitor combinations. The company’s shares fell 16% on Wednesday after...
07:00 , May 2, 2016 |  BC Week In Review  |  Clinical News

AGEN1884: Phase I started

Agenus began an open-label, dose-escalation, dose-expansion, U.S. Phase I trial to evaluate AGEN1884 in about 48 patients. The company gained the product through its 2014 acquisition of 4-Antibody AG . Agenus Inc. (NASDAQ:AGEN), Lexington, Mass....